PAK1 and melanoma: A recent study demonstrated that melanoma cells carrying the RAC1P29S mutation exhibit an augmented engagement of PAK1 (an immediate downstream effector of RAC1) in the presence of the RAC1P29S mutant and are thus highly sensitive to the PAK1 inhibitor [34].